Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0524A for Niacin-Induced Flushing
NCT00533611Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2007
- Primary completion
- Aug 2007
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of laropiprant in dyslipidemia, sponsored by Merck & Co.. Started Apr 2007; status: completed.
02
Drugs
laropiprant
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT00533611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00533611.